Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.13, sa.4, ss.497-504, 2003 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 4
- Basım Tarihi: 2003
- Doi Numarası: 10.1046/j.1525-1438.2003.13325.x
- Dergi Adı: INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.497-504
- Anahtar Kelimeler: chemotherapy, prognosis, recurrent cervical carcinoma, survival, GYNECOLOGIC-ONCOLOGY-GROUP, SQUAMOUS-CELL CARCINOMA, CISPLATIN PLUS IFOSFAMIDE, FIRST-LINE CHEMOTHERAPY, PHASE-II TRIAL, RANDOMIZED TRIAL, CANCER, PACLITAXEL, CYCLOPHOSPHAMIDE, BLEOMYCIN
- Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır
Özet
The aim of this study is to identify the impact of various prognostic factors on survival in patients with recurrent carcinoma of the uterine cervix. Fifty-two patients who were treated with platinum-based chemotherapy for recurrent or metastatic disease were retrospectively evaluated. Twenty-seven patients (90%) had received pelvic radiation as primary treatment.